)
)
)
Morphocell Technologies
ReLiver®, Morphocell’s first iPSC-derived engineered tissue, is an off-the-shelf therapeutic product currently in IND/CTA-enabling studies for acute and acute-on-chronic liver failure. Being developed as a transiently implanted, fully mature liver tissue, ReLiver® provides immediate metabolic and detoxification support, treats severe complications such as hepatic encephalopathy, and accelerates regeneration of the patient’s own liver.
Thanks to its immune-shielded encapsulation technology, ReLiver® operates without immunosuppression and without risk of rejection, offering a uniquely safe and minimally invasive alternative to liver transplantation for acute conditions. The approach is designed to significantly improve survival outcomes, potentially enabling complete recovery for many patients, and serving as a life-saving bridge for those with underlying chronic conditions.
Address
LavalQuebec
Canada
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)